Tag: Nasdaq:FBIO

Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025

National TV Segment Highlights FDA-Approved Treatment for Rosacea

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsNasdaq:FBIO